MARKET

DBVT

DBVT

Dbv Technologies S A
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.330
+0.040
+3.10%
Closed 16:00 05/18 EDT
OPEN
1.370
PREV CLOSE
1.290
HIGH
1.370
LOW
1.310
VOLUME
68.24K
TURNOVER
9.29K
52 WEEK HIGH
6.58
52 WEEK LOW
1.150
MARKET CAP
146.56M
P/E (TTM)
-1.7175
1D
5D
1M
3M
1Y
5Y
Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022
Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 001...
GlobeNewswire · 1d ago
DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting
Montrouge, France, May 12, 2022 DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting Shareholders Approved All Proposed Resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a cl...
GlobeNewswire · 6d ago
--Goldman Sachs Downgrades DBV Technologies to Neutral From Buy
MT Newswires · 05/10 09:05
DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)
Montrouge, France, May 5, 2022 DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM) DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “Company”), a...
GlobeNewswire · 05/04 23:30
BRIEF-Dbv Technologies Establishes An At-The-Market (ATM) Program On Nasdaq
reuters.com · 05/02 22:12
Notable earnings after Monday's close
AGNC, AMKR, AMRC, ANET, AWR, BGCP, BIGC, BRX, BSM, BXP, CACC, CAR, CBT, CC, CDLX, CHGG, CLX, CSR, CTRA, CVI, DBVT, OTCPK:DOCRF, DVN, DZSI, EARN, EVER, EXPE, FANG, FLS, FMC,
Seekingalpha · 05/01 21:35
Correction: DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments
Montrouge, France, April 26, 2022DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company,...
GlobeNewswire · 04/25 23:30
Ordinary and Extraordinary General Meeting of May 12, 2022
Montrouge, France, April 21, 2022Ordinary and Extraordinary General Meeting of May 12, 2022 Procedures for Obtaining Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical...
GlobeNewswire · 04/21 20:30
More
No Data
Learn about the latest financial forecast of DBVT. Analyze the recent business situations of Dbv Technologies S A through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
66.67%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average DBVT stock price target is 7.03 with a high estimate of 10.04 and a low estimate of 5.02.
High10.04
Average7.03
Low5.02
Current 1.330
EPS
Actual
Estimate
-0.51-0.42-0.34-0.25
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 88
Institutional Holdings: 24.55M
% Owned: 22.28%
Shares Outstanding: 110.19M
TypeInstitutionsShares
Increased
6
1.15M
New
9
203.08K
Decreased
7
6.11M
Sold Out
16
10.30M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.80%
Pharmaceuticals & Medical Research
-2.06%
Key Executives
Non-Executive Chairman/Independent Director
Michel De Rosen
Chief Executive Officer/Director
Daniel Tasse
Chief Financial Officer
Sebastien Robitaille
Other
Pharis Mohideen
Other
Michele Robertson
Non-Executive Director
Mailys Ferrere
Non-Executive Director
Michael Goller
Non-Executive Director
Julie O'Neill
Independent Director
Adora Ndu
Independent Director
Ravi Rao
Non-Executive Independent Director
Viviane Monges
Non-Executive Independent Director
Timothy Morris
Non-Executive Independent Director
Daniel Soland
No Data
No Data
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Webull offers kinds of DBV Technologies SA stock information, including NASDAQ:DBVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DBVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DBVT stock methods without spending real money on the virtual paper trading platform.